Strong half-year results from Australia's CSL

16 February 2016

Along with celebrating its 100th anniversary, Australian biotech firm CSL Limited (ASX: CSL) saw its shares rise 1.5% to A$106.00, after it posted record net profit after tax (NPAT) of $719 million (all figures US dollars) for the first-half fiscal year to December 31, up 4% on a reported basis when compared to the prior comparable period (PCP), and ahead of analysts’ estimates.

Earnings per share (EPS) grew 9%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying NPAT grew 7% and EPS grew 9%, at constant currency, the company noted.

Total sales for the period were $3,056 million, up 11% on PCP. Underlying sales were up 9% at constant currency. NPAT at $719 million was up 4% on PCP. Underlying NPAT was up 7% at constant currency. Earnings per share were $1.55, up 6% on PCP

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK